| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C9205 | Oxaliplatin | Eloxatin | unspecified | Chemotherapy | Alkylating Agent | Platinum Compound | No | 2002 | Jul 1, 2003 | Dec 31, 2005 | No Longer Used | |
| C9062 | Daratumumab Hyaluronidase | Darzalex Faspro | 10mg | Immunotherapy | Monoclonal Antibody | CD38 | No | 2020 | Oct 1, 2020 | Jan 1, 2021 | No Longer Used | |
| C9146 | Mirvetuximab soravtansine | Elahere | 1mg | Immunotherapy | Drug Antibody Conjugate | FR-alpha, DM4 | No | 2022 | Mar 17, 2023 | Jul 11, 2023 | No Longer Used | |
| J9094 | Cyclophosphamide | Cyclophosphamide lyophilized | 200 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Jan 1, 1994 | In Use | ||
| C9474 | Irinotecan | Onivyde | 1 mg | Chemotherapy | Topoisomerase I Inhibitor | Campothecin Analogs | No | 1996 | Jan 1, 2016 | In Use | ||
| J9118 | Calaspargase pegol-mknl | Asparlas | 10 units | Chemotherapy | Miscellaneous Agent | Enzyme | No | 2018 | Oct 1, 2019 | In Use | ||
| J9100 | Cytarabine | Cytarabine | 100 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 1998 | Jan 1, 1986 | In Use | ||
| C9131 | Ado-Trastuzumab Emtansine | Kadcyla | 1mg | Immunotherapy | Drug Antibody Conjugate | HER2 | No | 2013 | Jul 1, 2013 | Dec 31, 2013 | No Longer Used | |
| J9273 | Tisotumab vedodin-tftv | Tivdak | 1mg | Immunotherapy | Drug Antibody Conjugate | Tissue factor | No | 2021 | Mar 25, 2022 | In Use | ||
| J9150 | Daunorubicin | Daunorubicin Hydrochloride | 10 mg | Chemotherapy | Antitumor Antibiotic | Anthracycline | No | 1996 | Jan 1, 1986 | In Use | ||
| J0894 | Decitabine | Dacogen | 1 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 2006 | Jan 1, 2007 | In Use | ||
| J9172 | Docetaxel (Ingenus) | Docetaxel | 1mg | Chemotherapy | Antimitotic Agent | Taxane | No | 2017 | Dec 7, 2023 | In Use | ||
| J9185 | Fludarabine | Fludara | 50 mg | Chemotherapy | Antimetabolite | Purine Analog | No | 1991 | Jan 1, 1994 | In Use | ||
| J1190 | Dexrazoxane | Zinecard | 250 mg | Ancillary Therapy | Chemoprotective | Detoxifying Agent | No | 1995 | Jan 1, 2007 | In Use | ||
| Q9979 | Alemtuzumab | Lemtrada | 1 mg | Immunotherapy | Monoclonal Antibody | CD52 | No | 2001 | Oct 1, 2015 | Dec 31, 2015 | No Longer Used | |
| J9297 | Pemetrexed (Sandoz) | Pemetrexed (Sandoz) | 10mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2022 | Mar 17, 2023 | In Use | ||
| J9061 | Amivantamab | Rybrevant | 2mg | Immunotherapy | Monoclonal Antibody | EGFR, MET | No | 2021 | Jan 26, 2022 | In Use | ||
| NA | Dinutuximab | Unituxin | 3.5 mg/mL | Immunotherapy | Monoclonal Antibody | GD-2 | No | 2015 | In Use | |||
| C9424 | Daunorubicin | Daunorubicin Hydrochloride | 10 mg | Chemotherapy | Antitumor Antibiotic | Anthracycline | No | 1996 | Jan 1, 2004 | Dec 31, 2005 | No Longer Used | |
| J9352 | Trabectedin | Yondelis | 0.1mg | Chemotherapy | Alkylating Agent | Natural Product | No | 2015 | Jan 1, 2017 | In Use | ||
| J9173 | Durvalumab | Imfinzi | 10mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2017 | Jan 1, 2019 | In Use | ||
| J8562 | Fludarabine | Fludara | 10 mg | Chemotherapy | Antimetabolite | Purine Analog | No | 2008 | Jan 1, 2011 | Jan 1, 2026 | No Longer Used | |
| J9071 | Cyclophosphamide (AuroMedics) | Cyclophosphamide | 5mg | Chemotherapy | Alkylating Agent | Nitrogen mustard | No | 2021 | Mar 25, 2022 | In Use | ||
| J0640 | Leucovorin Calcium | Calcium leucovorin, Lederfoline, Leucosar, Leucovorin rescue, Wellcovorin | 50 mg | Ancillary Therapy | Chemoprotective | Antidote | No | 1952 | Jan 1, 1997 | In Use | ||
| J0896 | Luspatercept | Reblozyl | 0.25mg | Ancillary Therapy | Erythropoiesis-Stimulating Agent | No | 2019 | Jul 1, 2020 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home